Amgen Inc. (AMGN)
After hours:
| Previous Close | 254.88 |
| Open | 254.87 |
| Bid | 253.66 x 1000 |
| Ask | 255.34 x 800 |
| Day's Range | 252.54 - 255.50 |
| 52 Week Range | 214.39 - 296.67 |
| Volume | |
| Avg. Volume | 2,661,286 |
| Market Cap | 142.872B |
| Beta (5Y Monthly) | 0.58 |
| PE Ratio (TTM) | 21.01 |
| EPS (TTM) | 12.07 |
| Earnings Date | Feb 06, 2023 - Feb 10, 2023 |
| Forward Dividend & Yield | 7.76 (2.98%) |
| Ex-Dividend Date | Aug 17, 2022 |
| 1y Target Est | 254.85 |
- Zacks
Amgen (AMGN) Stock Sinks As Market Gains: What You Should Know
Amgen (AMGN) closed the most recent trading day at $254.88, moving -0.65% from the previous trading session.
- Reuters
UPDATE 2-U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals
Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics , and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November. "Given these companies' records of anti-competitive business practices, these acquisitions could cause further price increases on lifesaving drugs and prevent affordable alternatives from entering the market," she wrote in the letter to FTC Chair Lina Khan as well as Commissioners Rebecca Slaughter and Alvaro Bedoya, all of whom are Democrats.
- Reuters
U.S. Senator Warren 'particularly concerned' about Amgen, Indivior deals
WASHINGTON (Reuters) -Sen. Elizabeth Warren, an outspoken critic of corporate consolidation, wrote to the U.S. Federal Trade Commission to express concern about two pending pharmaceutical deals. In a letter dated Wednesday, Warren said that she was focused on Amgen's plan to buy Horizon Therapeutics, and addiction specialist Indivior's plan to buy Opiant for $145 million, which was announced in mid-November.
